Boston Scientific Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.2%projected annual EPS growth
Analyst Coverage
29analysts covering
FY Revenue (est.)
$21.4Bnext fiscal year
FY EPS (est.)
$3.30next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 26 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Organic Net Sales Growth Quarterly11.6%Target: 6.5% to 8.0% for FY 2026
Adjusted Operating Margin Quarterly28.0%Target: 31.0% by end of 2026
Electrophysiology (EP) Global Growth Rate Quarterly35.0%Target: ~10.0% global growth for FY 2026
Watch Items
- WATCHMAN Left Atrial Appendage Closure (LAAC) Standalone Procedure VolumeTrigger: Flat sequential U.S. sales in Q2 and Q3 2026Action: Monitor concomitant procedure growth and physician workflow constraints to assess if the slowdown is structural or temporary.
- FARAPULSE Pulsed Field Ablation (PFA) Market Share ErosionTrigger: U.S. EP growth slowing to mid-single digitsAction: Track competitive entries from Medtronic (PulseSelect, Sphere-9), Johnson & Johnson, and Abbott to evaluate duopoly dynamics.
- Penumbra Acquisition Integration and DilutionTrigger: Dilution of $0.06 to $0.08 per shareAction: Assess realization of synergies in neurovascular and peripheral vascular segments to offset near-term EPS drag.
Research as of 2 Sep 2026